Site-specific biases in phase-III clinical trials underestimate the effect of radical cure against Plasmodium vivax hypnozoites

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

JHH acknowledges funding from a National Science Foundation Graduate Research Fellowship and a Richard and Peggy Notebaert Premier Fellowship from the University of Notre Dame. CK received funding from NIH R21-AI137891. NN and MTW were supported by a grant from Medicine for Malaria Venture. NN also received funding from a Pasteur Roux-Cantarini Fellowship. This publication was made possible with partial support from Grant Numbers TL1 TR002531 and UL1TR002529 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB approval was not required for this work, because no human data was used.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes